Connect your AI

Protagonist Therapeutics PTGX Earnings yield

Earnings yield at other companies

Bristol-Myers SquibbBMY

5.9%+1.6pp

Eli LillyLLY

3.1%+1.6pp

AmgenAMGN

4.1%+0.6pp

IncyteINCY

7.6%+7.5pp

AbbVieABBV

0.9%-0.2pp

Apogee Therapeutics, Inc.APGE

-4.4%-1.5pp

Other financials

Income statement

Revenue$56.4M+99.0%

Operating income-$3.6M+81.1%

Net income$3.8M+132%

EPS (diluted)$0.05+126%

Balance sheet

Cash & equivalents$193.7M+38.7%

Total debt$9.8M-13.9%

Total equity$655.5M-4.9%

Total assets$697.5M-6.0%

Cash flow

Operating cash flow-$48.9M-139%

CapEx$215.0K-60.6%

Free cash flow-$49.2M-139%

Valuation

Market cap$7.26B+127%

Enterprise value$7.07B+130%

P/S98×+82.6×

Profitability

Operating margin-192.4%-205pp

Net margin-154.9%-182pp

FCF margin-12,264.3%-12,527pp

Returns & leverage

Return on equity-17.1%-26.1pp

Debt / equity0×0.0×

Current ratio17.8×+0.5×

Where this comes from

Calculated from Protagonist Therapeutics’s reported figures.

net income/market cap=-1.7%

Based on trailing twelve months.

The official record: Protagonist Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Protagonist Therapeutics's earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Protagonist Therapeutics's earnings yield?: Protagonist Therapeutics (PTGX) reported earnings yield of -1.7% in Q1 2026.
How has Protagonist Therapeutics's earnings yield changed year-over-year?: Protagonist Therapeutics's earnings yield decreased by 190.1% year-over-year, from 1.9% to -1.7%.
What is the long-term trend for Protagonist Therapeutics's earnings yield?: Over 4 years (2020 to 2025), Protagonist Therapeutics's earnings yield has grown at a -23.3% compound annual growth rate (CAGR), from -6.9% to -2.4%.
What does earnings yield mean?: Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.